Combretastatin A-4 phosphate
|Synonyms||CA4P; CA4PD; fosbretabulin; fosbretabulin disodium|
|Chemical and physical data|
|Molar mass||396.32 g/mol (exact mass : 396.097404)|
|3D model (Jmol)|
- For more information about this drug and its actions, see combretastatin.
Combretastatin A-4 phosphate (phosbretabulin, and its salt phosbretabulin disodium) is a microtubule destabilising drug, a type of vascular-targeting agent, a drug designed to damage the vasculature (blood vessels) of cancer tumours causing central necrosis. It is a derivative of combretastatin.
CA4P is also known as Fosbretabulin Tromethamine.
In July 2007 the pharmaceutical company OXiGENE initiated a 180-patient phase III clinical trial of CA-4-P in combination with carboplatin for the treatment of anaplastic thyroid cancer. There is currently no fully FDA approved treatment for this form of cancer.
- Combretastatin, e.g. for the chemical synthesis
- Combretastatin A-4 phosphate on www.cancer.gov
- A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers (GI-NETorPNET)
- Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
- Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors
- A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer (FALCON)
- CA4P clinical trials
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|